Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now full pipeline small index

Non-segmental Vitiligo: full-pipeline trial registry

5 of 10 indexed Non-segmental Vitiligo trials are currently recruiting.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Non-segmental Vitiligo: 10 US clinical trials tracked, 5 recruiting.

Non-segmental Vitiligo is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Incyte Corporation, running 4 of these trials.

Enrollment posture brief

Registry condition non-segmental-vitiligo

OPEN 5 | RECR 50% | LATE 4 | EARLY 6 | RANK #1724 | SPON 4

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Acute Leukemia of Ambiguous 80%Non-segmental Vitiligo (this)50%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Non-segmental Vitiligo

Non-segmental Vitiligo lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Non-segmental Vitiligo on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Non-segmental Vitiligo is recruiting above its size-band peers.

    5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Non-segmental Vitiligo research.

    Incyte Corporation accounts for 4 of 10 trials (40%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Non-segmental Vitiligo enrolment sits around 210 participants.

    Median target enrolment is 210 among the 10 trials that report a genuine target (sentinel values excluded). 2 of those (20%) plan for fewer than 100 participants.

  4. Non-segmental Vitiligo research is mostly interventional.

    10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 26Phase 34

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2 210 participants

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Novartis Pharmaceuticals

NCT07431177

RECRUITING Phase 2 200 participants

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

Takeda

NCT07108283

RECRUITING Phase 3 180 participants

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

Incyte Corporation

NCT06548360

RECRUITING Phase 2 45 participants

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

Elixiron Immunotherapeutics (Hong Kong)

NCT07223229

RECRUITING Phase 2 20 participants

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

Derm Texas, P

NCT07105254

ACTIVE NOT RECRUITING Phase 3 467 participants

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

Incyte Corporation

NCT06113445

ACTIVE NOT RECRUITING Phase 3 450 participants

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

Incyte Corporation

NCT06113471

ACTIVE NOT RECRUITING Phase 2 200 participants

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

Vyne Therapeutics

NCT06493578

COMPLETED Phase 3 330 participants

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

Incyte Corporation

NCT04052425

COMPLETED Phase 2 327 participants

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Ache Laboratorios Farmaceuticos S.A.

NCT04487860

Phase Distribution

PhaseTrial count
Phase 2 6
Phase 3 4

Named interventions

Most-linked intervention names on Non-segmental Vitiligo records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Povorcitinib Drug
2 trials
Placebo Other
2 trials
AS012 Drug
1 trials
Ruxolitinib cream Drug
1 trials
Vehicle Gel Drug
1 trials
VYN201 Gel Drug
1 trials
Roflumilast topical 0.3% foam Drug
1 trials

US sites by state

Facility locations filed on Non-segmental Vitiligo trials. A trial with sites in several states counts in each.

Florida 8 trials
California 7 trials
Alabama 6 trials
Michigan 5 trials
Arkansas 5 trials
Louisiana 4 trials
Arizona 4 trials
Texas 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Non-segmental Vitiligo page

10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 5 Non-segmental Vitiligo trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Incyte Corporation sponsors the most Non-segmental Vitiligo trials on record, review their full trial history before evaluating a specific study. See Incyte Corporation's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-segmental Vitiligo condition card totals 10 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.